Neurona Therapeutics Announces Presentation at the Oppenheimer 33rd Annual Healthcare…
<!-- Name:DistributionId Value:8783419 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Neurona Therapeutics
Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase…
<!-- Name:DistributionId Value:8748523 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Neurona Therapeutics Presents Clinical Case Study from First Human Trial of…
Clinical assessments three-months post-treatment report no serious adverse events and reduced seizure frequency to date in first trial participant Data Safety Monitoring Board clears…
Neurona Therapeutics Presents Preclinical Data at the American Academy of Neurology…
SAN FRANCISCO, April 01, 2022 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological…
Neurona Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare…
SAN FRANCISCO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing restorative neural cell therapies to treat chronic neurological…
Neurona Therapeutics Appoints Brad Margus to its Board of Directors
SAN FRANCISCO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a biotherapeutics company advancing restorative neural cell therapies for the treatment of chronic neurological…